Health Economics›Diffuse large B-cell lymphoma›Untreated randomized data

Untreated randomized data

Diffuse large B-cell lymphoma · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pola-R-CHP Variant #01	—	R 147 394	21d	—	—	8	R 936 175 PFS proxy	2
R-Hyper-CVAD/R-MA Variant #01	—	R 115 130	—	—	—	~4	~R 253 282 indirect	—
R2-CHOP Variant #01	—	R 29 124	21d	—	—	6	R 174 745 PFS proxy	1
R-miniCEOP Variant #01	—	R 28 707	21d	—	—	~6	~R 172 239 indirect	—
R-CEOP90 Variant #01	—	R 28 616	21d	—	—	8	R 223 508 PFS proxy	2
R-CEOP70 Variant #01	—	R 28 104	21d	—	—	8	R 220 436 PFS proxy	1
DA-R-EPOCH Variant #01	—	R 28 060	21d	—	—	8	R 224 478 PFS proxy	1
R-CHOEP-14 Variant #01	—	R 28 014	14d	—	—	~8	~R 172 301 indirect	—
R-MegaCHOP-14 Variant #01	—	R 27 284	14d	—	—	~6	~R 163 706 indirect	—
R-ACVBP Variant #01 Partial	—	R 27 016	14d	—	—	4	R 108 062 PFS proxy	2
R-CHOP (SC Rituximab) Variant #01 Partial	—	R 26 962	21d	—	—	~8	~R 34 361 indirect	—
R-CHOP (Prednisolone) Variant #01	—	R 26 953	21d	~42.4 mo	—	~3	~R 80 858 PFS proxy · indirect	—
R-CHOP-14 Variant #01	—	R 26 946	14d	—	—	~8	~R 215 569 indirect	—
R-CHOP-14 (SC Rituximab) Variant #01 Partial	—	R 26 946	14d	—	—	~8	~R 34 236 indirect	—
R-CHOP Variant #08	—	R 26 946	21d	—	—	9	R 242 515 PFS proxy	7
R-CHOP-14 (Prednisolone) Variant #01	—	R 26 789	14d	—	—	8	R 212 546 PFS proxy	1
R-miniCHOP (SC Rituximab) Variant #01 Partial	—	R 26 464	21d	—	—	~6	~R 29 261 indirect	—
R-THP-COP Variant #01 Partial	—	R 26 445	21d	—	—	~8	~R 211 564 indirect	—
Hi-CHOP Variant #01 Partial	—	R 1 041	21d	—	—	~6	~R 6 249 indirect	—

19 of 19 regimens shown